Banque Pictet & Cie SA Boosts Position in Danaher Corporation $DHR

Key Points

• Banque Pictet & Cie SA increased its stake in Danaher Corporation by 12.6%, owning 61,512 shares valued at $12.15 million after acquiring additional shares in Q2.
• Danaher reported earnings per share of $1.80, surpassing analyst expectations, and set FY 2025 guidance of 7.700-7.800 EPS while posting a revenue of $5.94 billion.
• A quarterly dividend of $0.32 was announced, reflecting a 0.7% dividend yield with a payout ratio of 27.23% for the company.

Banque Pictet & Cie SA lifted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 12.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,512 shares of the conglomerate's stock after acquiring an additional 6,868 shares during the quarter. Banque Pictet & Cie SA's holdings in Danaher were worth $12,151,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. boosted its stake in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the period. Smallwood Wealth Investment Management LLC bought a new stake in Danaher during the 1st quarter valued at approximately $31,000. Dunhill Financial LLC grew its holdings in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares during the period. Finally, Ameriflex Group Inc. bought a new position in shares of Danaher in the 4th quarter worth approximately $38,000. Institutional investors own 79.05% of the company's stock.

Danaher Stock Down 2.3%

Shares of Danaher stock opened at $181.56 on Friday. The company has a 50-day simple moving average of $199.54 and a two-hundred day simple moving average of $197.72. The stock has a market capitalization of $130.01 billion, a PE ratio of 38.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm earned $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Analysts Set New Price Targets

Several brokerages recently weighed in on DHR. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Bank of America reduced their target price on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Finally, Evercore ISI decreased their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.